-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Reiterates Buy on Celldex Therapeutics, Raises Price Target to $68

Benzinga·02/26/2026 14:19:40
Listen to the news
Stifel analyst Alex Thompson reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $58 to $68.